

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
Disposition Summary			
Animals Initially in Study	80	80	50
Early Deaths			
Accidently Killed			1
Moribund Sacrifice	27	16	18
Natural Death	4	11	6
Survivors			
Moribund Sacrifice			1
Terminal Sacrifice	21	25	24
Animals Examined Microscopically	52	52	50

ALIMENTARY SYSTEM

Esophagus	(51)	(52)	(50)
Muscularis, Inflammation			1 (2%)
Intestine Large, Cecum	(52)	(48)	(49)
Artery, Inflammation, Chronic Active		1 (2%)	2 (4%)
Intestine Large, Colon	(52)	(48)	(49)
Parasite Metazoan	1 (2%)	1 (2%)	1 (2%)
Artery, Inflammation, Chronic Active		1 (2%)	2 (4%)
Intestine Large, Rectum	(52)	(50)	(49)
Parasite Metazoan	2 (4%)	3 (6%)	2 (4%)
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)	5 (10%)
Intestine Small, Duodenum	(52)	(48)	(49)
Intestine Small, Ileum	(52)	(47)	(49)
Intestine Small, Jejunum	(52)	(48)	(49)
Liver	(52)	(49)	(49)
Angiectasis		2 (4%)	1 (2%)
Basophilic Focus	11 (21%)	1 (2%)	5 (10%)
Basophilic Focus, Multiple	4 (8%)		4 (8%)
Cholangiofibrosis		22 (45%)	10 (20%)
Clear Cell Focus	6 (12%)		3 (6%)
Clear Cell Focus, Multiple	9 (17%)		10 (20%)
Degeneration, Cystic	1 (2%)	2 (4%)	4 (8%)
Eosinophilic Focus	5 (10%)		7 (14%)
Eosinophilic Focus, Multiple		41 (84%)	13 (27%)
Fatty Change, Focal	2 (4%)		9 (18%)
Fatty Change, Diffuse	1 (2%)	48 (98%)	8 (16%)
Hematopoietic Cell Proliferation	19 (37%)	21 (43%)	31 (63%)
Hepatodiaphragmatic Nodule			1 (2%)
Hyperplasia, Nodular		43 (88%)	4 (8%)
Inflammation	21 (40%)	44 (90%)	47 (96%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
Mixed Cell Focus	6 (12%)	1 (2%)	2 (4%)
Mixed Cell Focus, Multiple	15 (29%)	6 (12%)	34 (69%)
Necrosis	1 (2%)	22 (45%)	14 (29%)
Pigmentation	1 (2%)	48 (98%)	43 (88%)
Toxic Hepatopathy		46 (94%)	36 (73%)
Bile Duct, Cyst	2 (4%)	21 (43%)	14 (29%)
Bile Duct, Fibrosis	2 (4%)		7 (14%)
Bile Duct, Hyperplasia	5 (10%)	40 (82%)	25 (51%)
Capsule, Inflammation	1 (2%)		
Centrilobular, Degeneration	1 (2%)	1 (2%)	2 (4%)
Hepatocyte, Hypertrophy		48 (98%)	30 (61%)
Hepatocyte, Multinucleated		43 (88%)	32 (65%)
Oval Cell, Hyperplasia		46 (94%)	29 (59%)
Mesentery	(2)	(9)	(9)
Artery, Inflammation, Chronic Active	1 (50%)	8 (89%)	5 (56%)
Artery, Thrombosis		1 (11%)	
Fat, Necrosis		1 (11%)	
Oral Mucosa	(1)	(3)	(0)
Gingival, Cyst		1 (33%)	
Pancreas	(52)	(47)	(49)
Amyloid Deposition			1 (2%)
Degeneration	1 (2%)		
Inflammation, Chronic Active		2 (4%)	4 (8%)
Acinus, Atrophy, Focal	4 (8%)	1 (2%)	4 (8%)
Acinus, Atrophy, Diffuse		1 (2%)	
Acinus, Vacuolization Cytoplasmic		42 (89%)	10 (20%)
Artery, Inflammation, Chronic Active	1 (2%)	12 (26%)	5 (10%)
Duct, Dilatation		3 (6%)	
Duct, Inflammation		2 (4%)	
Duct, Necrosis		1 (2%)	
Stomach, Forestomach	(52)	(51)	(49)
Hyperplasia, Squamous		3 (6%)	5 (10%)
Inflammation	2 (4%)	1 (2%)	4 (8%)
Ulcer	2 (4%)		3 (6%)
Artery, Inflammation, Chronic Active		1 (2%)	1 (2%)
Stomach, Glandular	(52)	(51)	(49)
Cyst	1 (2%)		
Erosion			2 (4%)
Mineralization			1 (2%)
Artery, Inflammation, Chronic Active		1 (2%)	
Tongue	(0)	(0)	(1)
Degeneration			1 (100%)
Tooth	(10)	(7)	(7)
Peridental Tissue, Inflammation	7 (70%)	6 (86%)	7 (100%)

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
CARDIOVASCULAR SYSTEM			
Blood Vessel	(52)	(51)	(50)
Heart	(52)	(50)	(50)
Cardiomyopathy	13 (25%)	16 (32%)	19 (38%)
Inflammation		1 (2%)	
Artery, Inflammation, Chronic Active		1 (2%)	
Coronary Artery, Thrombosis		1 (2%)	
Endocardium, Hyperplasia		2 (4%)	
Epicardium, Fibrosis		1 (2%)	
ENDOCRINE SYSTEM			
Adrenal Cortex	(52)	(49)	(49)
Atrophy	1 (2%)	35 (71%)	4 (8%)
Degeneration, Cystic	9 (17%)	8 (16%)	12 (24%)
Fibrosis			1 (2%)
Hematopoietic Cell Proliferation	1 (2%)		
Hyperplasia	14 (27%)	13 (27%)	21 (43%)
Hypertrophy	37 (71%)	34 (69%)	38 (78%)
Necrosis			4 (8%)
Vacuolization Cytoplasmic	10 (19%)	18 (37%)	21 (43%)
Adrenal Medulla	(52)	(49)	(49)
Hyperplasia	11 (21%)	1 (2%)	16 (33%)
Parathyroid Gland	(47)	(47)	(49)
Pituitary Gland	(52)	(52)	(50)
Angiectasis	1 (2%)		
Vacuolization Cytoplasmic			1 (2%)
Pars Distalis, Hyperplasia	10 (19%)	10 (19%)	10 (20%)
Thyroid Gland	(51)	(49)	(50)
Infiltration Cellular, Lymphocyte		1 (2%)	
Inflammation	1 (2%)		
C-cell, Hyperplasia	10 (20%)	11 (22%)	9 (18%)
Follicular Cell, Hypertrophy	6 (12%)	23 (47%)	12 (24%)
GENERAL BODY SYSTEM			
None			
GENITAL SYSTEM			
Clitoral Gland	(52)	(49)	(48)
Hyperplasia, Squamous			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
Inflammation	41 (79%)	13 (27%)	29 (60%)
Duct, Cyst	26 (50%)	30 (61%)	28 (58%)
Ovary	(52)	(48)	(49)
Cyst	8 (15%)	7 (15%)	10 (20%)
Inflammation		2 (4%)	1 (2%)
Uterus	(52)	(49)	(49)
Adenomyosis		1 (2%)	
Cyst		1 (2%)	
Hemorrhage		1 (2%)	2 (4%)
Inflammation	4 (8%)	4 (8%)	10 (20%)
Metaplasia, Squamous	29 (56%)	5 (10%)	23 (47%)
Thrombosis	1 (2%)		
Endometrium, Hyperplasia, Cystic	28 (54%)	9 (18%)	21 (43%)
Vagina	(7)	(0)	(0)

HEMATOPOIETIC SYSTEM

Bone Marrow	(52)	(52)	(50)
Atrophy	4 (8%)		
Hyperplasia	31 (60%)	47 (90%)	43 (86%)
Necrosis		1 (2%)	
Lymph Node	(0)	(2)	(1)
Bronchial, Ectasia		1 (50%)	
Bronchial, Hemorrhage		1 (50%)	
Lymph Node, Mandibular	(51)	(51)	(50)
Atrophy		1 (2%)	
Hyperplasia, Lymphoid		1 (2%)	
Hyperplasia, Plasma Cell	24 (47%)	19 (37%)	22 (44%)
Lymph Node, Mesenteric	(52)	(47)	(49)
Atrophy	1 (2%)		1 (2%)
Ectasia		1 (2%)	
Hemorrhage			2 (4%)
Hyperplasia, Plasma Cell	1 (2%)		
Spleen	(52)	(47)	(49)
Hematopoietic Cell Proliferation	42 (81%)	34 (72%)	43 (88%)
Hemorrhage	1 (2%)		
Necrosis	1 (2%)		
Pigmentation	39 (75%)	28 (60%)	31 (63%)
Lymphoid Follicle, Atrophy	3 (6%)	3 (6%)	1 (2%)
Red Pulp, Atrophy		3 (6%)	
Thymus	(51)	(49)	(50)
Atrophy	41 (80%)	44 (90%)	46 (92%)
Hemorrhage		3 (6%)	
Artery, Inflammation, Chronic Active		2 (4%)	

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
INTEGUMENTARY SYSTEM			
Mammary Gland	(52)	(50)	(50)
Cyst	1 (2%)		5 (10%)
Hyperplasia	4 (8%)	1 (2%)	4 (8%)
Inflammation, Granulomatous			4 (8%)
Skin	(52)	(51)	(50)
MUSCULOSKELETAL SYSTEM			
Bone	(52)	(52)	(50)
Fracture			1 (2%)
Skeletal Muscle	(0)	(0)	(2)
NERVOUS SYSTEM			
Brain	(52)	(52)	(50)
Gliosis	1 (2%)		
Hemorrhage	3 (6%)		1 (2%)
Hydrocephalus	1 (2%)		
Necrosis	2 (4%)		
Spinal Cord	(0)	(1)	(0)
Nerve, Degeneration		1 (100%)	
RESPIRATORY SYSTEM			
Lung	(51)	(50)	(50)
Hemorrhage		1 (2%)	
Inflammation	5 (10%)	2 (4%)	2 (4%)
Metaplasia, Squamous	1 (2%)	13 (26%)	
Pigmentation		1 (2%)	
Proteinosis	1 (2%)		
Alveolar Epithelium, Hyperplasia	4 (8%)		3 (6%)
Alveolar Epithelium, Metaplasia, Bronchiolar	6 (12%)	40 (80%)	32 (64%)
Alveolus, Infiltration Cellular, Histiocyte	36 (71%)	40 (80%)	40 (80%)
Artery, Mediastinum, Inflammation, Chronic		1 (2%)	
Active			
Nose	(52)	(52)	(50)
Cyst	1 (2%)		
Inflammation	1 (2%)	23 (44%)	8 (16%)
Glands, Cyst			1 (2%)

TDMS No. 20304 - 01
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/SD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 TEF evaluation (PCB 118)
 CAS Number: 31508-00-6

Date Report Requested: 07/14/2008
 Time Report Requested: 15:09:47
 First Dose M/F: NA / 03/26/04
 Lab: BAT

SPRAGUE-DAWLEY RATS FEMALE	0 UG/KG	4600 UG/KG	4600 UG/KG STOP
Nasolacrimal Duct, Inflammation, Suppurative		1 (2%)	
Olfactory Epithelium, Degeneration	1 (2%)	1 (2%)	
Olfactory Epithelium, Metaplasia		1 (2%)	1 (2%)
Respiratory Epithelium, Degeneration, Focal	1 (2%)		
Respiratory Epithelium, Hyperplasia	5 (10%)	27 (52%)	11 (22%)
Respiratory Epithelium, Metaplasia, Squamous			1 (2%)
Trachea	(51)	(52)	(50)
Inflammation		1 (2%)	
SPECIAL SENSES SYSTEM			
Eye	(52)	(52)	(50)
Cornea, Inflammation	1 (2%)		
Retina, Atrophy	1 (2%)	6 (12%)	
Harderian Gland	(52)	(52)	(50)
Infiltration Cellular, Mononuclear Cell	7 (13%)	13 (25%)	11 (22%)
URINARY SYSTEM			
Kidney	(52)	(50)	(49)
Accumulation, Hyaline Droplet	1 (2%)		2 (4%)
Amyloid Deposition			1 (2%)
Calculus Micro Observation Only	3 (6%)		
Cyst		1 (2%)	1 (2%)
Mineralization	25 (48%)	25 (50%)	28 (57%)
Nephropathy	42 (81%)	46 (92%)	48 (98%)
Pigmentation	2 (4%)	42 (84%)	6 (12%)
Artery, Inflammation, Chronic Active	1 (2%)		1 (2%)
Pelvis, Dilatation			3 (6%)
Pelvis, Inflammation		2 (4%)	2 (4%)
Transitional Epithelium, Hyperplasia		3 (6%)	
Ureter	(0)	(0)	(2)
Cyst			2 (100%)
Urinary Bladder	(52)	(50)	(49)
Inflammation			1 (2%)

*** END OF REPORT ***